

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

All items marked with an * are mandatory to complete
The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name: IceCure Medical * Website: www.icecure-medical.com *

CEO name: Eyal Shamir * Cell phone number: +972-52-322-6677*

Select a CATEGORY: Medical Devices

(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *

(Delete sessions you are not selecting)

3. **Are Cancer Therapeutics Fulfilling the Promise?**

9. **Are Medical Devices Still Relevant in the Context of New Biology?**

You may delete the section instructions, leaving only the bolded bullet title

Answers below should not exceed 60 words per question:

○ **Executive Summary / Investment Rational**

Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Lead by a highly experienced management team, IceCure Medical is setting new standards in minimally invasive cryoablation for treating benign and malignant tumors with the ProSense System. Our therapeutic focus is on minimally invasive, in-office breast cancer treatment (currently the first line of treatment is surgical excision), for which IceCure has promising interim study results - 96.91% reported no recurrence. There have been \$100M in investments to date.

○ **Core Technology**

What is the technology, its uniqueness, and its value proposition?

Our FDA-cleared and CE-marked ProSense™ Cryoablation System utilizes Liquid Nitrogen (LN2) to generate ultra-cold temperatures quickly for maximum efficacy in tumor destruction. Other systems use argon gas which is more costly and has certain safety restrictions. LN2 creates colder, more lethal temperatures and enables in office-procedures. Our main value proposition is our US based clinical data in the successful treatment of breast cancer, which no other ablation technology has.

○ **Product Profile/Pipeline**

Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

IceCure has submitted a De Novo application with the FDA for early-stage, low-risk breast cancer in patients at high risk to surgery, representing approximately 43,000 US new patients annually. IceCure has a strong relationship with the American Society of Breast Surgeons and plans to implement a registry to continue to gather data on breast cancer cryoablation. Additionally, a CPT III code is in place with a facility fee of ~\$3,400, pending FDA clearance

- **Business Strategy**

Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

ProSense is actively sold across the US, EU, and Asia. In the US, IceCure's strategy is focused on breast cancer and selling directly to breast surgeons and radiology clinics. In the rest of the world, IceCure sells to medical providers through distributors. IceCure has an exclusive distribution agreement with Shanghai Medtronic for Mainland China and recently received regulatory clearance to commence sales. The company also has distribution agreements with Terumo in Japan and Thailand.

- **What's Next?**

R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

IceCure is looking to expand its regulatory approvals in various territories, especially for breast cancer in the US. Additionally, we plan to initiate a breast cancer cryoablation registry with the ASBrS. In order to commercialize our breast cancer solution in US, we plan to increase significantly our sales force. IceCure is developing the next generation of its LN2 based cryoablation technology to offer solutions for additional clinical indications, and tumor sizes and locations. IceCure has received US, EU, and Japanese patents for its novel "Cryo Pump."